Résumés
Résumé
L’importance des glucocorticoïdes dans le développement et le maintien de l’obésité ainsi que la genèse de ses complications métaboliques et cardio-vasculaires est maintenant bien reconnue. L’existence, chez l’obèse, de concentrations circulantes de cortisol normales a fait envisager la possibilité d’anomalies du métabolisme local des glucocorticoïdes, en particulier dans le tissu adipeux. Un ensemble de données récentes a mis en évidence, dans ce tissu, une surexpression de la 11β-hydroxystéroïde déshydrogénase de type 1, enzyme qui convertit la cortisone (inactive) en cortisol (actif). Cette surexpression engendre un hypercorticisme local. Le développement d’inhibiteurs spécifiques de la 11β-hydroxystéroïde déshydrogénase de type 1 pourrait constituer une nouvelle approche du traitement de l’obésité viscérale et de ses complications.
Summary
Glucocorticoids are implicated as a pathophysiological mediator of obesity and its accompanying metabolic and cardiovascular complications. Obese patients exhibit normal circulating cortisol levels, related to increased glucocorticoid production and degradation. However, it has been demonstrated that local production of active cortisol from inactive cortisone driven by 11β-hydroxysteroid dehydrogenase type 1 is exaggerated in adipose tissue of obese subjects. Such local hypercortisolism may be responsible for increased adipocyte differentiation and enhanced secretion of free fatty acids and other substances involved in the metabolic and cardiovascular complications observed in obesity.
Parties annexes
Références
- 1. Vague J. La différenciation sexuelle, facteur déterminant des formes de l’obésité. Presse Med 1947; 30: 339-40.
- 2. Bamberger CM, Schulte HM, Chrousos GP. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrinol Rev 1996; 17: 245-61.
- 3. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11β-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001; 15: 61-78.
- 4. Walker BR. Steroid metabolism in metabolic syndrome X. Best Pract Res Clin Endocrinol Metab 2001; 15: 111-22.
- 5. Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001; 86: 1418-21.
- 6. Björntorp P, Rosmond R. The metabolic syndrome: a neuroendocrine disorder? Br J Nutr 2000; 83: S49-57.
- 7. Jessop DS, Dallman MF, Fleming D, Lightman SL. Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 2001; 86: 4109-14.
- 8. Rask E, Walker BR, Söderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002; 87: 3330-6.
- 9. Livingstone DEW, Jones GC, Smith K, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000; 141: 560-3.
- 10. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70.
- 11. Katz JR, Mohamed-Ali V, Wood PJ, Yudkin JS, Coppack SW. An in vivo study of the cortisol-cortisone shuttle in subcutaneous abdominal adipose tissue. Clin Endocrinol 1999; 50: 63-8.
- 12. Bujalska IW, Kumar S, Stewart PM. Does central obesity reflect Cushing’s disease of the omentum? Lancet 1997; 349: 1210-3.
- 13. Bujalska IJ, Kumar S, Hewinson M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 1999; 140: 3188-96.
- 14. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M. Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002; 87: 2701-5.
- 15. Bujalska IJ, Walker EA, Hewinson M, Stewart PM. A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002; 87: 1205-10.
- 16. Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002; 22: 173-8.
- 17. Seckl JR, Walker BR. 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001; 142: 1371-6.
- 18. Weaver JU, Thaventhiran L, Noonan N, et al. The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 1994; 41: 639-48.
- 19. Berger J, Tanen M, Elbrecht A, et al. Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 2001; 276: 12629-35.
- 20. Kelly IE, Han TS, Walsh K, Lean MEJ. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-93.